Do analysts rate MTVA or ORGS?

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 1,251.35%. Given MetaVia's stronger consensus rating and higher probable upside, analysts plainly believe MetaVia is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MetaVia 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is MTVA or ORGS more profitable?

MetaVia has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat MetaVia's return on equity. Company Net Margins Return on Equity Return on Assets MetaVia N/A -172.92% -89.39% Orgenesis -3,827.81% N/A -130.18%

Do analysts rate APRE or ORGS?

Aprea Therapeutics presently has a consensus target price of $4.07, suggesting a potential upside of 543.46%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aprea Therapeutics is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, OBSV or ORGS?

Orgenesis has higher revenue and earnings than ObsEva. Orgenesis is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ObsEva N/A N/A -$58.38M -$0.92 N/A Orgenesis $662K 3.12 -$55.36M -$11.51 N/A

Is OBSV or ORGS more profitable?

ObsEva has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets ObsEva N/A -416.36% -92.01% Orgenesis -3,827.81% N/A -130.18%

Do analysts prefer CNSP or ORGS?

CNS Pharmaceuticals presently has a consensus target price of $20.00, indicating a potential upside of 282.41%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe CNS Pharmaceuticals is more favorable than Orgenesis. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CNS Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Orgenesis 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is ORGS or NKGN more profitable?

NKGen Biotech has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Company Net Margins Return on Equity Return on Assets Orgenesis -3,827.81% N/A -130.18% NKGen Biotech N/A N/A -479.36%

Orgenesis (ORGS) Competitors

$0.40 0.00 (0.00%)

As of 07/24/2026

Compare

ORGS vs. MTVA, APRE, OBSV, CNSP, and NKGN

Should you buy Orgenesis stock or one of its competitors? MarketBeat compares Orgenesis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Orgenesis include MetaVia (MTVA), Aprea Therapeutics (APRE), ObsEva (OBSV), CNS Pharmaceuticals (CNSP), and NKGen Biotech (NKGN). These companies are all part of the "pharmaceutical products" industry.

How does Orgenesis compare to MetaVia?

MetaVia (NASDAQ:MTVA) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, valuation, institutional ownership, risk, profitability, dividends, analyst recommendations and media sentiment.

MetaVia has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat MetaVia's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
MetaVia	N/A	-172.92%	-89.39%
Orgenesis	-3,827.81%	N/A	-130.18%

MetaVia has higher earnings, but lower revenue than Orgenesis. MetaVia is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
MetaVia	N/A	N/A	-$12.97M	-$5.19	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

MetaVia has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.14, suggesting that its stock price is 214% more volatile than the broader market.

In the previous week, MetaVia had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for MetaVia and 0 mentions for Orgenesis. MetaVia's average media sentiment score of 0.44 beat Orgenesis' score of 0.00 indicating that MetaVia is being referred to more favorably in the media.

Company	Overall Sentiment
MetaVia	Neutral
Orgenesis	Neutral

MetaVia presently has a consensus price target of $20.00, indicating a potential upside of 1,251.35%. Given MetaVia's stronger consensus rating and higher probable upside, analysts plainly believe MetaVia is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
MetaVia	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

1.4% of MetaVia shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 0.6% of MetaVia shares are owned by insiders. Comparatively, 1.9% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

MetaVia beats Orgenesis on 9 of the 15 factors compared between the two stocks.

How does Orgenesis compare to Aprea Therapeutics?

Aprea Therapeutics (NASDAQ:APRE) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, media sentiment, risk, profitability, analyst recommendations and dividends.

Aprea Therapeutics presently has a consensus target price of $4.07, suggesting a potential upside of 543.46%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Aprea Therapeutics is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Orgenesis has a net margin of -3,827.81% compared to Aprea Therapeutics' net margin of -4,405.59%. Orgenesis' return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%
Orgenesis	-3,827.81%	N/A	-130.18%

34.2% of Aprea Therapeutics shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 10.5% of Aprea Therapeutics shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Aprea Therapeutics has higher earnings, but lower revenue than Orgenesis. Aprea Therapeutics is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

Aprea Therapeutics has a beta of 1.5, indicating that its stock price is 50% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.14, indicating that its stock price is 214% more volatile than the broader market.

In the previous week, Aprea Therapeutics had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for Aprea Therapeutics and 0 mentions for Orgenesis. Aprea Therapeutics' average media sentiment score of 1.87 beat Orgenesis' score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Aprea Therapeutics	Very Positive
Orgenesis	Neutral

Summary

Aprea Therapeutics beats Orgenesis on 10 of the 15 factors compared between the two stocks.

How does Orgenesis compare to ObsEva?

ObsEva (NASDAQ:OBSV) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment.

In the previous week, ObsEva had 1 more articles in the media than Orgenesis. MarketBeat recorded 1 mentions for ObsEva and 0 mentions for Orgenesis. ObsEva's average media sentiment score of 0.00 equaled Orgenesis'average media sentiment score.

Company	Overall Sentiment
ObsEva	Neutral
Orgenesis	Neutral

Orgenesis has higher revenue and earnings than ObsEva. Orgenesis is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

17.5% of ObsEva shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 14.4% of ObsEva shares are owned by insiders. Comparatively, 1.9% of Orgenesis shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

ObsEva has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ObsEva	N/A	-416.36%	-92.01%
Orgenesis	-3,827.81%	N/A	-130.18%

ObsEva has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, Orgenesis has a beta of 3.14, meaning that its share price is 214% more volatile than the broader market.

Summary

ObsEva beats Orgenesis on 6 of the 11 factors compared between the two stocks.

How does Orgenesis compare to CNS Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Orgenesis (NASDAQ:ORGS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings, valuation and dividends.

CNS Pharmaceuticals has a beta of 3.06, suggesting that its stock price is 206% more volatile than the broader market. Comparatively, Orgenesis has a beta of 3.14, suggesting that its stock price is 214% more volatile than the broader market.

In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Orgenesis. MarketBeat recorded 2 mentions for CNS Pharmaceuticals and 0 mentions for Orgenesis. CNS Pharmaceuticals' average media sentiment score of 1.44 beat Orgenesis' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Orgenesis	Neutral

CNS Pharmaceuticals presently has a consensus target price of $20.00, indicating a potential upside of 282.41%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe CNS Pharmaceuticals is more favorable than Orgenesis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Orgenesis	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

14.0% of CNS Pharmaceuticals shares are owned by institutional investors. Comparatively, 22.6% of Orgenesis shares are owned by institutional investors. 0.0% of CNS Pharmaceuticals shares are owned by company insiders. Comparatively, 1.9% of Orgenesis shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

CNS Pharmaceuticals has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%. Orgenesis' return on equity of 0.00% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-238.68%	-166.30%
Orgenesis	-3,827.81%	N/A	-130.18%

CNS Pharmaceuticals has higher earnings, but lower revenue than Orgenesis. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A

Summary

Orgenesis beats CNS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Orgenesis compare to NKGen Biotech?

Orgenesis (NASDAQ:ORGS) and NKGen Biotech (NYSE:NKGN) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, profitability, analyst recommendations, earnings and media sentiment.

Orgenesis has higher revenue and earnings than NKGen Biotech. NKGen Biotech is trading at a lower price-to-earnings ratio than Orgenesis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Orgenesis	$662K	3.12	-$55.36M	-$11.51	N/A
NKGen Biotech	N/A	N/A	-$82.94M	-$1.68	N/A

Orgenesis has a beta of 3.14, indicating that its stock price is 214% more volatile than the broader market. Comparatively, NKGen Biotech has a beta of 0.65, indicating that its stock price is 35% less volatile than the broader market.

NKGen Biotech has a net margin of 0.00% compared to Orgenesis' net margin of -3,827.81%.

Company	Net Margins	Return on Equity	Return on Assets
Orgenesis	-3,827.81%	N/A	-130.18%
NKGen Biotech	N/A	N/A	-479.36%

In the previous week, Orgenesis' average media sentiment score of 0.00 equaled NKGen Biotech'saverage media sentiment score.

Company	Overall Sentiment
Orgenesis	Neutral
NKGen Biotech	Neutral

22.6% of Orgenesis shares are held by institutional investors. Comparatively, 76.2% of NKGen Biotech shares are held by institutional investors. 1.9% of Orgenesis shares are held by insiders. Comparatively, 10.4% of NKGen Biotech shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

NKGen Biotech beats Orgenesis on 5 of the 9 factors compared between the two stocks.

Get Orgenesis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ORGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ORGS vs. The Competition

Export

Metric	Orgenesis	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$2.07M	$975.11M	$6.87B	$12.26B
Dividend Yield	N/A	4.84%	2.67%	9.79%
P/E Ratio	-0.03	1.53	27.14	23.64
Price / Sales	3.12	105.75	517.06	88.99
Price / Cash	N/A	20.06	50.54	59.64
Price / Book	-0.06	8.47	10.28	6.07
Net Income	-$55.36M	-$2.70M	$3.60B	$331.99M
7 Day Performance	N/A	-2.29%	-1.27%	-0.63%
1 Month Performance	N/A	-3.97%	-0.37%	-2.00%
1 Year Performance	-60.00%	27.39%	18.30%	13.62%

Orgenesis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ORGS Orgenesis	N/A	$0.40 flat	N/A	-96.0%	$2.07M	$662K	N/A	150
MTVA MetaVia	1.8888 of 5 stars	$1.58 flat	$20.00 +1,165.8%	-81.7%	$8.16M	N/A	N/A	8	Analyst Forecast Short Interest Increase Gap Down
APRE Aprea Therapeutics	4.1421 of 5 stars	$0.66 +1.2%	$4.07 +516.2%	-67.3%	$8.07M	$290K	N/A	7	Gap Up
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50
CNSP CNS Pharmaceuticals	4.0393 of 5 stars	$5.80 +7.6%	$20.00 +244.8%	-39.1%	$7.88M	N/A	N/A	5	Short Interest Decrease

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ORGS) was last updated on 7/25/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Orgenesis (ORGS) Competitors

ORGS vs. MTVA, APRE, OBSV, CNSP, and NKGN

How does Orgenesis compare to MetaVia?

Summary

How does Orgenesis compare to Aprea Therapeutics?

Summary

How does Orgenesis compare to ObsEva?

Summary

How does Orgenesis compare to CNS Pharmaceuticals?

Summary

How does Orgenesis compare to NKGen Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Orgenesis (ORGS) Competitors

ORGS vs. MTVA, APRE, OBSV, CNSP, and NKGN

How does Orgenesis compare to MetaVia?

Is MTVA or ORGS more profitable?

Which has stronger earnings and valuation, MTVA or ORGS?

Which has more volatility and risk, MTVA or ORGS?

Does the media refer more to MTVA or ORGS?

Do analysts rate MTVA or ORGS?

Do insiders and institutionals have more ownership in MTVA or ORGS?

Summary

How does Orgenesis compare to Aprea Therapeutics?

Do analysts rate APRE or ORGS?

Is APRE or ORGS more profitable?

Do insiders & institutionals hold more shares of APRE or ORGS?

Which has stronger valuation & earnings, APRE or ORGS?

Which has more volatility & risk, APRE or ORGS?

Does the media prefer APRE or ORGS?

Summary

How does Orgenesis compare to ObsEva?

Does the media favor OBSV or ORGS?

Which has better valuation and earnings, OBSV or ORGS?

Do institutionals & insiders have more ownership in OBSV or ORGS?

Is OBSV or ORGS more profitable?

Which has more volatility and risk, OBSV or ORGS?

Summary

How does Orgenesis compare to CNS Pharmaceuticals?

Which has more risk & volatility, CNSP or ORGS?

Does the media prefer CNSP or ORGS?

Do analysts prefer CNSP or ORGS?

Do insiders and institutionals believe in CNSP or ORGS?

Is CNSP or ORGS more profitable?

Which has preferable valuation & earnings, CNSP or ORGS?

Summary

How does Orgenesis compare to NKGen Biotech?

Which has preferable valuation & earnings, ORGS or NKGN?

Which has more volatility and risk, ORGS or NKGN?

Is ORGS or NKGN more profitable?

Does the media favor ORGS or NKGN?

Do insiders and institutionals have more ownership in ORGS or NKGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORGS vs. The Competition

Orgenesis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools